Literature DB >> 27354744

Carboplatin and Liposomal Doxorubicin for Ovarian Cancer.

Jamie Nguyen, Dominic A Solimando, J Aubrey Waddell.   

Abstract

The complexity of cancer chemotherapy requires pharmacists be familiar with the complicated regimens and highly toxic agents used. This column reviews various issues related to preparation, dispensing, and administration of antineoplastic therapy, and the agents, both commercially available and investigational, used to treat malignant diseases. Questions or suggestions for topics should be addressed to Dominic A. Solimando, Jr, President, Oncology Pharmacy Services, Inc., 4201 Wilson Blvd #110-545, Arlington, VA 22203, e-mail: OncRxSvc@comcast.net; or J. Aubrey Waddell, Professor, University of Tennessee College of Pharmacy; Oncology Pharmacist, Pharmacy Department, Blount Memorial Hospital, 907 E. Lamar Alexander Parkway, Maryville, TN 37804, e-mail: waddfour@charter.net.

Entities:  

Year:  2016        PMID： 27354744      PMCID： PMC4911983          DOI： 10.1310/hpj5106-442

Source DB:  PubMed          Journal:  Hosp Pharm        ISSN： 0018-5787


  40 in total

Review 1.  Pathophysiology, severity, pattern, and risk factors for carboplatin-induced emesis.

Authors:  A du Bois; W Vach; M Kiechle; U Cramer-Giraud; H G Meerpohl
Journal:  Oncology       Date:  1996-06       Impact factor: 2.935

2.  2006 update of recommendations for the use of white blood cell growth factors: an evidence-based clinical practice guideline.

Authors:  Thomas J Smith; James Khatcheressian; Gary H Lyman; Howard Ozer; James O Armitage; Lodovico Balducci; Charles L Bennett; Scott B Cantor; Jeffrey Crawford; Scott J Cross; George Demetri; Christopher E Desch; Philip A Pizzo; Charles A Schiffer; Lee Schwartzberg; Mark R Somerfield; George Somlo; James C Wade; James L Wade; Rodger J Winn; Antoinette J Wozniak; Antonio C Wolff
Journal:  J Clin Oncol       Date:  2006-05-08       Impact factor: 44.544

3.  Carboplatin and pegylated liposomal doxorubicin versus carboplatin and paclitaxel in partially platinum-sensitive ovarian cancer patients: results from a subset analysis of the CALYPSO phase III trial.

Authors:  L Gladieff; A Ferrero; G De Rauglaudre; C Brown; P Vasey; A Reinthaller; E Pujade-Lauraine; N Reed; D Lorusso; S Siena; H Helland; L Elit; S Mahner
Journal:  Ann Oncol       Date:  2011-10-05       Impact factor: 32.976

4.  American Society of Clinical Oncology guideline for antiemetics in oncology: update 2006.

Authors:  Mark G Kris; Paul J Hesketh; Mark R Somerfield; Petra Feyer; Rebecca Clark-Snow; James M Koeller; Gary R Morrow; Lawrence W Chinnery; Maurice J Chesney; Richard J Gralla; Steven M Grunberg
Journal:  J Clin Oncol       Date:  2006-05-22       Impact factor: 44.544

5.  Ovarian cancer in elderly patients: carboplatin and pegylated liposomal doxorubicin versus carboplatin and paclitaxel in late relapse: a Gynecologic Cancer Intergroup (GCIG) CALYPSO sub-study.

Authors:  J E Kurtz; M C Kaminsky; A Floquet; A S Veillard; R Kimmig; A Dorum; L Elit; M Buck; E Petru; N Reed; G Scambia; N Varsellona; C Brown; E Pujade-Lauraine
Journal:  Ann Oncol       Date:  2011-03-14       Impact factor: 32.976

6.  Pegylated liposomal Doxorubicin and Carboplatin compared with Paclitaxel and Carboplatin for patients with platinum-sensitive ovarian cancer in late relapse.

Authors:  Eric Pujade-Lauraine; Uwe Wagner; Elisabeth Aavall-Lundqvist; Val Gebski; Mark Heywood; Paul A Vasey; Birgit Volgger; Ignace Vergote; Sandro Pignata; Annamaria Ferrero; Jalid Sehouli; Alain Lortholary; Gunnar Kristensen; Christian Jackisch; Florence Joly; Chris Brown; Nathalie Le Fur; Andreas du Bois
Journal:  J Clin Oncol       Date:  2010-05-24       Impact factor: 44.544

7.  Carboplatin dosing in overweight and obese patients with normal renal function, does weight matter?

Authors:  Corine Ekhart; Sjoerd Rodenhuis; Jan H M Schellens; Jos H Beijnen; Alwin D R Huitema
Journal:  Cancer Chemother Pharmacol       Date:  2008-11-07       Impact factor: 3.333

8.  Carboplatin dose calculation in lung cancer patients with low serum creatinine concentrations using CKD-EPI and Cockcroft-Gault with different weight descriptors.

Authors:  Dieter Kaag
Journal:  Lung Cancer       Date:  2012-11-04       Impact factor: 5.705

9.  Efficacy of pegylated liposomal doxorubicin (PLD) plus carboplatin in ovarian cancer patients who recur within six to twelve months: a phase II study.

Authors:  Patti Power; Gavin Stuart; Amit Oza; D Provencher; James R Bentley; Wilson H Miller; Jean-François Pouliot
Journal:  Gynecol Oncol       Date:  2009-06-10       Impact factor: 5.482

10.  Final overall survival results of phase III GCIG CALYPSO trial of pegylated liposomal doxorubicin and carboplatin vs paclitaxel and carboplatin in platinum-sensitive ovarian cancer patients.

Authors:  U Wagner; C Marth; R Largillier; J Kaern; C Brown; M Heywood; T Bonaventura; I Vergote; M C Piccirillo; R Fossati; V Gebski; E P Lauraine
Journal:  Br J Cancer       Date:  2012-07-26       Impact factor: 7.640
View more
  2 in total

1.  Controlled Drug Release and Cytotoxicity Studies of Beta-Lapachone and Doxorubicin Loaded into Cyclodextrins Attached to a Polyethyleneimine Matrix.

Authors:  Agata Kowalczyk; Artur Kasprzak; Magdalena Poplawska; Monika Ruzycka; Ireneusz P Grudzinski; Anna M Nowicka
Journal:  Int J Mol Sci       Date:  2020-08-14       Impact factor: 6.208

Review 2.  Antioxidant Supplementation in the Treatment of Neurotoxicity Induced by Platinum-Based Chemotherapeutics-A Review.

Authors:  Jelena S Katanic Stankovic; Dragica Selakovic; Vladimir Mihailovic; Gvozden Rosic
Journal:  Int J Mol Sci       Date:  2020-10-20       Impact factor: 5.923
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.